Why the study?
Malignant hypertension remains a severe condition requiring early treatment, but in the absence of robust clinical trials, there are no formal treatment guidelines.
Answers are grounded in this paper and cite their sources.
This review summarizes the pathophysiological evidence and current consensus for treating malignant hypertension, highlighting the potential utility of oral renin-angiotensin system blockers.
: Malignant hypertension (MHT) still remains a severe condition that requires early recognition and treatment. Over the years, the prevention and treatment of MHT have significantly advanced through the introduction of modern antihypertensive agents. However, in the absence of robust clinical trials, there remain no formal guidelines on the treatment of MHT. This review summarizes the historical background and pathophysiological evidence of MHT, which has led to common practices in its pharmacological management but can also introduce challenges. The current consensus for treatment involves early intravenous infusion of antihypertensive agents, but oral blockers of the renin-angiotensin system may improve the management of MHT, and it offers a suitable treatment option in low-income countries where the condition remains relatively prevalent.
No takes yet. Share an insight, caveat, or question.
Gosse et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: